ArticleScientific reports2017
Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Liver Disease and Plant-Derived Phytoconstituents: From Ethnopharmacology to Modern Medicine.Phytotherapy research : PTR · 2026Review
- Apigenin as an emerging hepatoprotective agent: current status and future perspectives.Frontiers in pharmacology · 2024Review
- Pharmacology and mechanisms of apigenin in preventing osteoporosis.Frontiers in pharmacology · 2024Review
- Insights into the pharmacological and therapeutic effects of apigenin in liver injuries and diseases.Heliyon · 2023Article
- Apigenin inhibits fibrous scar formation after acute spinal cord injury through TGFβ/SMADs signaling pathway.CNS neuroscience & therapeutics · 2022Article
- Hepatic fibrosis 2022: Unmet needs and a blueprint for the future.Hepatology (Baltimore, Md.) · 2022Review
- Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies.Journal of internal medicine · 2022Review
- Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis.Scientific reports · 2021Article
- [Quantitative analysis of differential proteins in liver tissues of patients with non-alcoholic steatohepatitis using iTRAQ technology].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Review
- Wild Bitter Melon Extract Regulates LPS-Induced Hepatic Stellate Cell Activation, Inflammation, Endoplasmic Reticulum Stress, and Ferroptosis.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Weighted correlation network bioinformatics uncovers a key molecular biosignature driving the left-sided heart failure.BMC medical genomics · 2020Article
- Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma.Cancer prevention research (Philadelphia, Pa.) · 2020Article
- Nine hub genes related to the prognosis of HBV-positive hepatocellular carcinoma identified by protein interaction analysis.Annals of translational medicine · 2020Article
- Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing.Bioinformatics (Oxford, England) · 2019Article
- Apigenin inhibits fibroblast proliferation and reduces epidural fibrosis by regulating Wnt3a/β-catenin signaling pathway.Journal of orthopaedic surgery and research · 2019Article
- MoDeSuS: A Machine Learning Tool for Selection of Molecular Descriptors in QSAR Studies Applied to Molecular Informatics.BioMed research international · 2019Article
- The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases.Oxidative medicine and cellular longevity · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
Abstract
We have used a computational approach to identify anti-fibrotic therapies by querying a transcriptome. A transcriptome signature of activated hepatic stellate cells (HSCs), the primary collagen-secreting cell in liver, and queried against a transcriptomic database that quantifies changes in gene expression in response to 1,309 FDA-approved drugs and bioactives (CMap). The flavonoid apigenin was among 9 top-ranked compounds predicted to have anti-fibrotic activity; indeed, apigenin dose-dependently reduced collagen I in the human HSC line, TWNT-4. To identify proteins mediating apigenin's effect, we next overlapped a 122-gene signature unique to HSCs with a list of 160 genes encoding proteins that are known to interact with apigenin, which identified C1QTNF2, encoding for Complement C1q tumor necrosis factor-related protein 2, a secreted adipocytokine with metabolic effects in liver. To validate its disease relevance, C1QTNF2 expression is reduced during hepatic stellate cell activation in culture and in a mouse model of alcoholic liver injury in vivo, and its expression correlates with better clinical outcomes in patients with hepatitis C cirrhosis (n = 216), suggesting it may have a protective role in cirrhosis progression.These findings reinforce the value of computational approaches to drug discovery for hepatic fibrosis, and identify C1QTNF2 as a potential mediator of apigenin's anti-fibrotic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.